The findings from CheckMate 040 (42) and CheckMate 459 (50) trials highlight the need for further investigation to determine the relationship between baseline PD-L1 expression levels and treatment benefits in HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.